XERS

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company founded in 2005 and headquartered in Chicago, Illinois. The company went public in June 2018 and focuses on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has successfully transitioned from a development-stage company to a commercial-stage biopharmaceutical enterprise with three marketed products and a growing pipeline. The company leverages its proprietary formulation technology platforms, XeriSol and XeriJect, to create innovative drug delivery solutions for both its own products and through technology partnerships with other pharmaceutical companies.